International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 2 , Pages 421-429 , 1 June 2010

Influence of Pathological Nodal Status and Maximal Standardized Uptake Value of the Primary Tumor and Regional Lymph Nodes on Treatment Plans in Patients With Advanced Oral Cavity Squamous Cell Carcinoma

  • Chun-Ta Liao, M.D.

      Affiliations

    • Department of Otorhinolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Department of Head and Neck Oncology Group, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • ,
  • Hung-Ming Wang, M.D.

      Affiliations

    • Department of Head and Neck Oncology Group, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Department of Medical Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • ,
  • Joseph Tung-Chieh Chang, M.D., M.H.A.

      Affiliations

    • Department of Head and Neck Oncology Group, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Department of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • ,
  • Chien-Yu Lin

      Affiliations

    • Department of Head and Neck Oncology Group, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Department of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • ,
  • Shu-Hang Ng, M.D.

      Affiliations

    • Department of Head and Neck Oncology Group, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Department of Diagnostic Radiology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • ,
  • Shiang-Fu Huang, M.D.

      Affiliations

    • Department of Otorhinolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Department of Head and Neck Oncology Group, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • ,
  • I.-How Chen, M.D.

      Affiliations

    • Department of Otorhinolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Department of Head and Neck Oncology Group, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • ,
  • Chuen Hsueh, M.D.

      Affiliations

    • Department of Head and Neck Oncology Group, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Department of Pathology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • ,
  • Li-Yu Lee, M.D.

      Affiliations

    • Department of Head and Neck Oncology Group, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Department of Pathology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • ,
  • Chih-Hung Lin, M.D.

      Affiliations

    • Department of Head and Neck Oncology Group, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • ,
  • Ann-Joy Cheng, Ph.D.

      Affiliations

    • Department of Head and Neck Oncology Group, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Department of Medical Biotechnology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • ,
  • Tzu-Chen Yen, M.D., Ph.D.

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Department of Head and Neck Oncology Group, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
    • Corresponding Author InformationReprint requests to: Tzu-Chen Yen, MD, PhD, Department of Nuclear Medicine, Chang Gung Memorial Hospital at Linko, No. 5, Fu-Hsing ST., Kwei-Shan, Taoyuan, Taiwan, R.O.C. Tel: 886-3328 1200, ext. 2673; Fax: 886-3211 0052

Received 4 March 2009 ,Revised 1 May 2009 ,Accepted 4 May 2009.

References 

  1. Liao CT, Chang JT, Wang HM, et al. Analysis of risk factors predictive of local tumor control in oral cavity cancer. Ann Surg Oncol. 2008;15:915–922
  2. Liao CT, Chang JT, Wang HM, et al. Survival in squamous cell carcinoma of the oral cavity: Differences between pT4N0 and other stage IVA categories. Cancer. 2007;110:564–571
  3. Fleming ID, Cooper JS, Henson DE, et al. AJCC cancer staging manual. 5th ed.. Philadelphia: Lippincott-Raven; 1997;
  4. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed.. New York: Springer-Verlag; 2002;
  5. Liao CT, Chang JT, Wang HM, et al. Surgical outcome of T4a and resected T4b oral cavity cancer. Cancer. 2006;107:337–344
  6. Liao CT, Ng SH, Chang JT, et al. T4b oral cavity cancer below the mandibular notch is resectable with a favorable outcome. Oral Oncol. 2007;43:570–579
  7. Liao CT, Chang JT, Wang HM, et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys. 2009;73:764–771
  8. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. J Clin Oncol. 2003;21:3651–3658
  9. Wang HM, Wang CS, Chen JS, et al. Cisplatin, tegafur, and leucovorin: A moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002;94:2989–2995
  10. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996;36:999–1004
  11. Allal AS, Slosman DO, Kebdani T, et al. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-d-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295–1300
  12. Halfpenny W, Hain SF, Biassoni L, et al. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86:512–516
  13. Suzuki H, Hasegawa Y, Terada A, et al. FDG-PET predicts survival and distant metastasis in oral squamous cell carcinoma. Oral Oncol 2009 (in press).
  14. Ng SH, Yen TC, Chang JT, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol. 2006;24:4371–4376
  15. Wensing BM, Vogel WV, Marres HA, et al. FDG-PET in the clinically negative neck in oral squamous cell carcinoma. Laryngoscope. 2006;116:809–813
  16. Schoder H, Carlson DL, Kraus DH, et al. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med. 2006;47:755–762
  17. Ng SH, Yen TC, Liao CT, et al. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: A prospective study of 124 patients with histologic correlation. J Nucl Med. 2005;46:1136–1143
  18. Yen TC, Chang JT, Ng SH, et al. Staging of untreated squamous cell carcinoma of buccal mucosa with 18F-FDG PET: Comparison with head and neck CT/MRI and histopathology. J Nucl Med. 2005;46:775–781
  19. Stoeckli SJ, Steinert H, Pfaltz M, et al. Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck. 2002;24:345–349
  20. Nakasone Y, Inoue T, Oriuchi N, et al. The role of whole-body FDG-PET in preoperative assessment of tumor staging in oral cancers. Ann Nucl Med. 2001;15:505–512
  21. Stuckensen T, Kovacs AF, Adams S, et al. Staging of the neck in patients with oral cavity squamous cell carcinomas: A prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg. 2000;28:319–324
  22. Myers LL, Wax MK. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer. J Otolaryngol. 1998;27:342–347
  23. Braams JW, Pruim J, Nikkels PG, et al. Nodal spread of squamous cell carcinoma of the oral cavity detected with PET-tyrosine, MRI and CT. J Nucl Med. 1996;37:897–901
  24. Kovacs AF, Dobert N, Gaa J, et al. Positron emission tomography in combination with sentinel node biopsy reduces the rate of elective neck dissections in the treatment of oral and oropharyngeal cancer. J Clin Oncol. 2004;22:3973–3980
  25. Kunkel M, Helisch A, Reichert TE, et al. Clinical and prognostic value of [(18)F]FDG-PET for surveillance of oral squamous cell carcinoma after surgical salvage therapy. Oral Oncol. 2006;42:297–305
  26. Kunkel M, Forster GJ, Reichert TE, et al. Detection of recurrent oral squamous cell carcinoma by [18F]-2-fluorodeoxyglucose-positron emission tomography: Implications for prognosis and patient management. Cancer. 2003;98:2257–2265
  27. Kunkel M, Forster GJ, Reichert TE, et al. Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol. 2003;39:170–177
  28. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199–4208
  29. McCollum AD, Burrell SC, Haddad RI, et al. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004;26:890–896
  30. Yao M, Graham MM, Hoffman HT, et al. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2004;59:1001–1010
  31. Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck. 1997;19:666–674
  32. Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398–1404
  33. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907–1911
  34. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg. 2004;130:1361–1367
  35. Kim SY, Roh JL, Kim MR, et al. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med. 2007;48:752–757
  36. Kim SY, Roh JL, Kim JS, et al. Utility of FDG PET in patients with squamous cell carcinomas of the oral cavity. Eur J Surg Oncol. 2008;34:208–215
  37. Liao CT, Chang JT, Wang HM, et al. Preoperative 18F-FDG PET standardized uptake value of neck lymph nodes predicts neck control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys (in press).

 Chun-Ta Liao and Hung-Ming Wang contributed equally to this work.

 Conflict of interest: none.

PII: S0360-3016(09)00716-0

doi: 10.1016/j.ijrobp.2009.05.002

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 2 , Pages 421-429 , 1 June 2010

Article Tools

* Image Usage & Resolution